$9.03
17.27% yesterday
Nasdaq, May 20, 10:14 pm CET
ISIN
US2825591033
Symbol
ETNB
Sector
Industry

89bio Inc Stock price

$9.03
+2.76 44.02% 1M
+1.05 13.16% 6M
+1.21 15.47% YTD
+0.09 1.01% 1Y
+5.91 189.42% 3Y
-18.55 67.26% 5Y
-11.77 56.59% 10Y
Nasdaq, Closing price Tue, May 20 2025
+1.33 17.27%
ISIN
US2825591033
Symbol
ETNB
Sector
Industry

Key metrics

Market capitalization $1.32b
Enterprise Value $717.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.18
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-403.29m
Free Cash Flow (TTM) Free Cash Flow $-399.93m
Cash position $638.78m
EPS (TTM) EPS $-3.38
P/E forward negative
Short interest 16.51%
Show more

Is 89bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

89bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a 89bio Inc forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a 89bio Inc forecast:

Buy
82%
Hold
18%

Financial data from 89bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
56% 56%
-
-0.04 -0.04
56% 56%
-
- Selling and Administrative Expenses 41 41
27% 27%
-
- Research and Development Expense 362 362
146% 146%
-
-403 -403
124% 124%
-
- Depreciation and Amortization 0.04 0.04
56% 56%
-
EBIT (Operating Income) EBIT -403 -403
124% 124%
-
Net Profit -387 -387
134% 134%
-

In millions USD.

Don't miss a Thing! We will send you all news about 89bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

89bio Inc Stock News

Neutral
GlobeNewsWire
11 days ago
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified s...
Neutral
GlobeNewsWire
14 days ago
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in the following investor conferences during the month of ...
Neutral
GlobeNewsWire
19 days ago
– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are expected in...
More 89bio Inc News

Company Profile

89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.

Head office United States
CEO Rohan Palekar
Employees 93
Founded 2018
Website www.89bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today